Adolescents with moderate-to-severe atopic dermatitis or eczema could benefit from Dupilumab, according to results of a phase IIa open-label trial and a subsequent phase III open-label extension trial.
The results from these latest studies, which are reported in the British Journal of Dermatology, demonstrate the long-term safety and efficacy of the medication for up to 52 weeks of treatment.
Dupilumab works by stopping the action of certain substances in the body that cause the symptoms of eczema. Specifically, it is a monoclonal antibody against interleukin-4 receptor alpha.
"Results from these trials show that dupilumab provides substantial and sustained clinical benefit to these patients with an acceptable safety profile."